lactulose (cephulac) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. It is administered orally for constipation, and either orally or rectally for hepatic encephalopathy. It generally begins working after 8–12 hours, but may take up to 2 days to improve constipation.   Wikipedia

Chemistry

  • SMILES: O.OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
  • InChIKey: XVCHNXZRPZGVJA-MILSHCHSSA-N
  • Mol. Mass: 360.31
  • ALogP: -5.4
  • ChEMBL Molecule:
    lactulose  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1560 - $8.0908
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-o-beta-d-galactopyranosyl-d-fructofuranose | 4-o-beta-d-galactopyranosyl-d-fructose | acilac | bifiteral | cephulac | cholac | chronulac | constilac | constulose | crystalline lactulose | d-lactulose | duphalac | duphalac dry | enulose | evalose | generlac | heptalac | isolactose | lactulone | lactulosa | lactulose | lactulose hydrate | lactulosum | lattulose | laxilose | laxose orange | lemlax | osmolax | portalac | regulose

Organizations (131)

Research & Development (108)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (1)


 

Constipation

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Acute-On-Chronic Liver Failure (Phase 4)

Bone Diseases, Metabolic (Phase 4)

Burns (Phase 1)

Colonoscopy (Phase 3)

Constipation ()

Crohn Disease (Early Phase 1)

Dermatitis, Atopic (Phase 2/Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Dyspepsia (Phase 4)

Enterocolitis, Necrotizing (Phase 2)

Fecal Impaction (Phase 2)

Fibrosis (Phase 4)

Fissure in Ano (Phase 4)

Hamartoma (Phase 4)

Hemorrhoids (Phase 4)

Hepatic Encephalopathy (Phase 4)

Hypertension, Portal (Phase 4)

Infant, Premature, Diseases (Phase 1)

Intestinal Diseases (Phase 4)

Intestinal Neoplasms (Phase 1)

Intestines (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 4)

Ondansetron (Phase 4)

Pathologic Processes (Phase 4)

Persian Gulf Syndrome (Phase 1)

Renal Insufficiency (Phase 4)

Sepsis (Phase 2)

Treatment Outcome (Phase 3)

Trematode Infections (Phase 4)

Vaginosis, Bacterial (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 108

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue